Although our results highlight exendin 2029 as a promising candidate for developing safer peptide analgesics targeting TRPV1, the translation of these findings into clinical practice requires further investigation
Others respond less robustly, even with optimal dose, diet, and exercise
That finding alone should make exercise non-negotiable
For most users, the compounded version delivers similar benefits at a much lower price point
The behaviour of the final solution also depends on the peptides purity, salt form, residual solvents, counterions, lyophilisation quality, moisture exposure, storage history, excipients, sequence length, hydrophobicity, and pH profile